These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21735680)

  • 1. [Experimental quality assessment of APTT-control reagent kits in the study of heparin-containing plasma in therapeutic ranges].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 Apr; (4):39-41. PubMed ID: 21735680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental quality assessment of APTT-control reagent kits in the study of plasma with varying Factor VIII activity].
    Staritsyna NN; Shanskaia AI; Papaian LP; Ivanova RP
    Klin Lab Diagn; 2011 May; (5):31-3. PubMed ID: 21786611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of reagent batch on activated partial thromboplastin time in canine plasma and use of the ratio system for standardization].
    Mischke R
    Berl Munch Tierarztl Wochenschr; 2002; 115(5-6):225-9. PubMed ID: 12058600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.
    Dudek MM; Harris LF; Killard AJ
    Int J Lab Hematol; 2011 Jun; 33(3):272-80. PubMed ID: 21118388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in heparin sensitivity of APTT reagents.
    Bjornsson TD; Nash PV
    Am J Clin Pathol; 1986 Aug; 86(2):199-204. PubMed ID: 3739971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of argatroban on the activated partial thromboplastin time: a comparison of 21 commercial reagents.
    Francis JL; Hursting MJ
    Blood Coagul Fibrinolysis; 2005 Jun; 16(4):251-7. PubMed ID: 15870544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH
    Clin Lab Sci; 2012; 25(3):142-8. PubMed ID: 22953513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time.
    Brandt JT; Triplett DA
    Am J Clin Pathol; 1981 Oct; 76(4 Suppl):530-7. PubMed ID: 7282639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring the efficiency of heparin anticoagulation in patients on programmed hemodialysis].
    Berkovskiĭ AL; Sergeeva EV; Suvorov AV; Mondoev LG; Kabardina MS; Biriukova LS; Kozlov AA
    Klin Lab Diagn; 2010 Dec; (12):30-2. PubMed ID: 21395052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.
    Klein RH; van der Vorst MM; de Wilde RB; Hogenbirk K; de Kam ML; Burggraaf J
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):327-31. PubMed ID: 23337708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma.
    Zanke B; Shojania AM
    Am J Clin Pathol; 1990 May; 93(5):684-9. PubMed ID: 2183588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.